The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Gritstone Bio; MedImmune; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Roche
Research Funding - Amgen; Merck Serono
 
Ka Yeung Mark Wong
Consulting or Advisory Role - Baxalta; Baxalta
Speakers' Bureau - Sirtex Medical
Travel, Accommodations, Expenses - MSD Oncology
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Fabio Gelsomino
No Relationships to Disclose
 
Massimo Aglietta
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck; Novartis
Research Funding - AstraZeneca (Inst); PharmaMar
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; MERCK; tesaro
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Bayer; Boehringer Ingelheim; Eisai; EMD Serono; Etubics; Exelixis; Genentech/Roche; Ipsen; Lexicon; Lilly; Merck; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Ipsen; Lexicon; Merck; Novartis; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University
 
Eric Van Cutsem
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen-Cilag; Pfizer; Roche
 
Andrew G Hill
Employment - Tasman Oncology
Leadership - Tasman Oncology
Stock and Other Ownership Interests - Tasman Oncology
Research Funding - Bristol-Myers Squibb; Tasman Oncology
 
Michael B. Sawyer
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; Ipsen; LEO Pharma; Merck; Novartis; nutricia; pfizer; Sanofi; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - Celgene; Immuneering; LEO Pharma; Nutricia; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer
 
Alain Hendlisz
No Relationships to Disclose
 
Bart Neyns
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Speakers' Bureau - Novartis
Research Funding - Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
 
Magali Svrcek
Consulting or Advisory Role - Bristol-Myers Squibb
 
Ajlan Atasoy
No Relationships to Disclose
 
Huanyu Zhao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Ming Lei
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene
Patents, Royalties, Other Intellectual Property - Columbia University
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Biocartis; EMD Serono; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Merck; Navire; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; PRMA Consulting; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Guardant Health; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech